Independent European studies presented at CTAD 2025 and ADPD2026 confirmed that the HISCL™ p-Tau217 RUO* and the HISCL™ Aβ42/40 ratio are highly accurate for early identification of Aβ pathology. By using a routine blood draw, results are available in just 17 minutes.
Sysmex Europe SE has announced the availability of the HISCL™ automated immunoassay system for Alzheimer’s blood biomarker testing, offering a fast, fully automated and non-invasive alternative to traditional CSF- and PET-based pathways. Supported by clinical data from independent research centres, the HISCL™ platform is now available for laboratory use, with the CE-IVD marked Aβ42/40 ratio assay and HISCL™ p-Tau217 RUO* accessible under Research Use Only (RUO) access.
The findings were recently presented at the Clinical Trials on Alzheimer’s Disease (CTAD) and the ADPD Alzheimer’s & Parkinson’s Disease Conference and demonstrate a strong analytical and diagnostic performance across sensitivity, specificity, and predictive values using a standard venous blood sample.
Diagnostic gap
Despite research advances, more than 90% of patients with mild cognitive impairment (MCI) remain undiagnosed or misdiagnosed in primary care, frequently presenting late in the disease course after early intervention opportunities have narrowed or closed. Lumbar puncture is invasive and resource-intensive, presenting barriers for clinicians, while PET imaging is expensive and not uniformly available.
Blood biomarkers are widely recognised as the next step in closing this gap. But a reliable measurement of blood biomarkers requires ultrasensitive technologies, capable of delivering reliable results within routine workflows, without specialist infrastructure or bespoke handling.
Independently validated by leading research centres
The HISCL™ platform’s diagnostic performance has been independently validated by leading research centres – the Neurochemistry Laboratory, Amsterdam UMC, led by Professor Charlotte Teunissen, and Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau, Barcelona, led by doctor Daniel Alcolea – each using different patient populations and reference standards.
Across studies, HISCL™ p-Tau217 RUO* and the HISCL™ p-Tau217 RUO* /Aβ42 ratio consistently achieved AUROC values above 0.90, with strong performance across sensitivity, specificity, PPV, and NPV. The results support the use of the platform as a first-line triage tool for Alzheimer’s-related amyloid pathology in both research and clinical settings.
HISCL™ platform
The HISCL™ system is engineered for practical deployment in clinical laboratory environments, with no dedicated Alzheimer’s testing infrastructure required. HISCL™ works within existing automated setups, with a standard blood draw as the only pre-analytical requirement.
Key features include:
- 17 minutes for sample measurement
- Fully automated, random-access platform requiring no specialist training
- Non-invasive sample collection via standard venous blood draw, with no lumbar puncture
- CE-IVD marked Aβ42/40 ratio assay, available for laboratory use
- HISCL™ p-Tau217 RUO* and HISCL™ p-Tau217 RUO*/Aβ42 assays available under RUO access
- Truly scalable, from major academic centres and memory clinics to district general hospital labs
- Studies demonstrated close performance compared to gold-standard CSF and PET reference methods.
